UNASSIGNED: This was a retrospective cohort study at King Abdulaziz Medical City (KAMC) for all critically ill adult patients who received IV colistin. Eligible patients were classified into two groups based on the ascorbic acid use as concomitant therapy within three days of colistin initiation. The primary outcome was CIN odds after colistin initiation, while the secondary outcomes were 30-day mortality, in-hospital mortality, ICU, and hospital LOS. Propensity score (PS) matching was used (1:1 ratio) based on the patient\'s age, SOFA score, and serum creatinine.
UNASSIGNED: A total of 451 patients were screened for eligibility; 90 patients were included after propensity score matching based on the selected criteria. The odds of developing CIN after colistin initiation were similar between patients who received ascorbic acid (AA) as adjunctive therapy compared to patients who did not (OR (95 %CI): 0.83 (0.33, 2.10), p-value = 0.68). In addition, the 30-day mortality, in-hospital mortality, ICU, and hospital LOS were similar between the two groups.
UNASSIGNED: Adjunctive use of Ascorbic acid during colistin therapy was not associated with lower odds of CIN. Further studies with a larger sample size are required to confirm these findings.
UNASSIGNED:本研究是在阿卜杜勒阿齐兹国王医疗城(KAMC)进行的一项回顾性队列研究,研究对象是所有接受静脉粘菌素治疗的成年危重患者。根据在粘菌素开始后三天内使用抗坏血酸作为伴随疗法,将符合条件的患者分为两组。主要结果是粘菌素启动后的CIN几率,而次要结局是30天死亡率,住院死亡率,ICU,医院LOS根据患者的年龄使用倾向评分(PS)匹配(1:1比例),SOFA得分,还有血清肌酐.
UNASSIGNED:共筛选451名患者是否符合资格;90名患者根据所选标准进行倾向评分匹配后纳入。与未接受抗坏血酸(AA)辅助治疗的患者相比,粘菌素开始后发生CIN的几率相似(OR(95CI):0.83(0.33,2.10),p值=0.68)。此外,30天死亡率,住院死亡率,ICU,两组的住院LOS相似.
未经证实:在粘菌素治疗期间辅助使用抗坏血酸与较低的CI几率无关。需要更大样本量的进一步研究来证实这些发现。